Stock Track | BioCryst Shares Plunge Despite Record Q3 Revenue on Earnings Miss

Stock Track

2024-11-04

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) saw its shares plummet over 6% in pre-market trading on November 4, 2024, after the company reported mixed third-quarter financial results. While BioCryst achieved record revenue, driven by strong sales of its flagship product ORLADEYO, the company's earnings missed analysts' expectations, prompting the sell-off.

For the third quarter ended September 30, 2024, BioCryst reported a GAAP net loss of $14.0 million, or $0.07 per share, falling short of analysts' consensus estimate of a $0.06 loss per share. This marked a significant improvement from the $36.1 million loss, or $0.19 per share, recorded in the same period last year.

Despite the earnings miss, BioCryst's revenue surged 35.1% year-over-year to $117.1 million, exceeding analysts' expectations. The company's ORLADEYO net revenue, which accounts for the majority of its sales, grew an impressive 35.7% to $116.3 million, driven by strong patient demand and continued market penetration.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1154571416"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1154571416\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1154571416?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-04 22:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154571416","market":"us","top_or_hot":-1,"title":"Stock Track | BioCryst Shares Plunge Despite Record Q3 Revenue on Earnings Miss","media":"Stock Track","content":"<p>BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) saw its shares plummet over 6% in pre-market trading on November 4, 2024, after the company reported mixed third-quarter financial results. While BioCryst achieved record revenue, driven by strong sales of its flagship product ORLADEYO, the company's earnings missed analysts' expectations, prompting the sell-off.</p>\n\n<p>For the third quarter ended September 30, 2024, BioCryst reported a GAAP net loss of $14.0 million, or $0.07 per share, falling short of analysts' consensus estimate of a $0.06 loss per share. This marked a significant improvement from the $36.1 million loss, or $0.19 per share, recorded in the same period last year.</p>\n\n<p>Despite the earnings miss, BioCryst's revenue surged 35.1% year-over-year to $117.1 million, exceeding analysts' expectations. The company's ORLADEYO net revenue, which accounts for the majority of its sales, grew an impressive 35.7% to $116.3 million, driven by strong patient demand and continued market penetration.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BioCryst Shares Plunge Despite Record Q3 Revenue on Earnings Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BioCryst Shares Plunge Despite Record Q3 Revenue on Earnings Miss\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2024-11-04 22:33</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) saw its shares plummet over 6% in pre-market trading on November 4, 2024, after the company reported mixed third-quarter financial results. While BioCryst achieved record revenue, driven by strong sales of its flagship product ORLADEYO, the company's earnings missed analysts' expectations, prompting the sell-off.</p>\n\n<p>For the third quarter ended September 30, 2024, BioCryst reported a GAAP net loss of $14.0 million, or $0.07 per share, falling short of analysts' consensus estimate of a $0.06 loss per share. This marked a significant improvement from the $36.1 million loss, or $0.19 per share, recorded in the same period last year.</p>\n\n<p>Despite the earnings miss, BioCryst's revenue surged 35.1% year-over-year to $117.1 million, exceeding analysts' expectations. The company's ORLADEYO net revenue, which accounts for the majority of its sales, grew an impressive 35.7% to $116.3 million, driven by strong patient demand and continued market penetration.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCRX","symbol_name":"BioCryst製藥","start_time":0,"source_url":"","article_id":"1154571416","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154571416","pubTimestamp":1730730828,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BioCryst Pharmaceuticals Inc.  saw its shares plummet over 6% in pre-market trading on November 4, 2024, after the company reported mixed third-quarter financial results. While BioCryst achieved record revenue, driven by strong sales of its flagship product ORLADEYO, the company's earnings missed analysts' expectations, prompting the sell-off.For the third quarter ended September 30, 2024, BioCryst reported a GAAP net loss of $14.0 million, or $0.07 per share, falling short of analysts' consensu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BCRX":"BioCryst制药"},"translate_title":"尽管第三季度营收创历史新高，但BioCryst股价仍暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCRX":1},"content_text":"BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) saw its shares plummet over 6% in pre-market trading on November 4, 2024, after the company reported mixed third-quarter financial results. While BioCryst achieved record revenue, driven by strong sales of its flagship product ORLADEYO, the company's earnings missed analysts' expectations, prompting the sell-off.\nFor the third quarter ended September 30, 2024, BioCryst reported a GAAP net loss of $14.0 million, or $0.07 per share, falling short of analysts' consensus estimate of a $0.06 loss per share. This marked a significant improvement from the $36.1 million loss, or $0.19 per share, recorded in the same period last year.\nDespite the earnings miss, BioCryst's revenue surged 35.1% year-over-year to $117.1 million, exceeding analysts' expectations. The company's ORLADEYO net revenue, which accounts for the majority of its sales, grew an impressive 35.7% to $116.3 million, driven by strong patient demand and continued market penetration.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}